DaVita HealthCare Partners Inc. 3rd Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
DaVita (DVA) PT Trimmed to $90 at Piper Jaffray Post Q3; Maintains 'Overweight'
November 4, 2015 8:47 AM ESTPiper Jaffray analyst Kevin Ellich lowered his price target on DaVita (NYSE: DVA) to $90.00 (from $92.00) but maintained an Overweight rating.
Ellich commented, "While Q3 results beat Street estimates and HCP's operating income improved, DVA faces a number of potential headwinds that could reduce HCP's operating... More
DaVita (DVA) Tops Q3 EPS by 3c, Offers Outlook
November 3, 2015 4:40 PM ESTDaVita (NYSE: DVA) reported Q3 EPS of $1.00, $0.03 better than the analyst estimate of $0.97. Revenue for the quarter came in at $3.53 billion versus the consensus estimate of $3.46 billion.
Outlook
We are updating our consolidated operating income for 2015 to now be in the range of $1.870 billion to $1.915 billion.
Our... More
